SEC Form 4 · accession 0001144204-18-047656
Cytosorbents Corp · CTSO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Al Kraus
Director
Period of report
Aug 30, 2018
Accepted (ET)
Aug 31, 2018 · 8:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 30, 2018 | M | 8,000 | $2.10 | A | 133,046 | D | |
| Common Stock | Aug 30, 2018 | M | 18,000 | $4.20 | A | 151,046 | D | |
| Common StockF2,F3 | Aug 30, 2018 | S | 26,000 | $14.4724 | D | 125,046 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.10 | Aug 30, 2018 | M | 8,000 | D | Jan 8, 2009 | Jan 8, 2019 | Common Stock | 8,000 | 0 | D |
| Stock Option (right to buy)F1 | $4.20 | Aug 30, 2018 | M | 18,000 | D | — | Jan 28, 2019 | Common Stock | 18,000 | 0 | D |
Explanation of responses
- F1The stock options issued to the reporting person became exercisable according to the following vesting schedule: 4,500 stock options vested on 1/28/2009; 4,500 stock options vested on 1/28/2010; 4,500 stock options vested on 1/28/2011; and 4,500 stock options vested on 1/28/2012.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $14.605. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Includes (a) the following restricted stock units subject to vesting upon a "Change in Control" of CytoSorbents Corporation (the "Company"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (i) 3,300 restricted stock units granted on March 15, 2018, (ii) 6,000 restricted stock units granted on February 24, 2017, (iii) 5,000 restricted stock units granted on June 7, 2016, and (iv) 55,000 restricted stock units granted on April 8, 2015, and (b) 55,746 shares of common stock owned by the reporting person.